Andrew Naylor

Chief Operating Officer

Nottinghamshire, England, United Kingdom

About

Andrew Naylor has over 19 years’ experience in materials R&D. He specialises in the set up and running of R&D operations for materials processing, characterisation and formulation development. He excels at project management and technical problem solving, driving projects to completion on track and on budget. He has worked as Head of R&D Operations for 4D Biomaterials since September 2020, setting up the company’s labs and R&D operations. Specialities: Polymers, Thermal Analysis, Project Management, Formulation Development, Supercritical Fluids, High Pressure Processing and Equipment

Experience

  • 4D Biomaterials (Nottingham, England, United Kingdom)
    • Chief Operating Officer
      Jan 2024 - Present · 2 yrs 6 mos

    • Head of R&D Operations
      Sep 2020 - Present · 5 yrs 10 mos

      • Building and maintaining the R+D operations of the business • Developing and scaling up the production of 3D printable, biodegradable resins, and optimising production process control to deliver the required product specifications. • Developing the analysis, testing and characterisation of resins and 3D printed parts • Leading the development of a product range with properties tailored to suit specific applications

  • R&D Director at Upperton Limited
    Aug 2015 - Sep 2020 · 5 yrs 2 mos

    • Built and managed a team of R&D scientists to deliver client projects covering a wide range of molecules and dosage forms, from small molecules to complex biologics • Key member of management team delivering significant business expansion, with 5 fold increase in staff numbers and turnover in 3 years, including a successful relocation of business operations with minimal downtime • Managed a successful collaborative H2020 grant worth >€1.6m to deliver a cold chain independent vaccine product using nasal sprays and oral capsules. Project was completed on time and under budget, and met all milestones • Took a key role in team leading the expansion of business into IMP manufacture, and managed a team setting up a new QC laboratory, including procurement of equipment and set up of QMS to support the laboratory. The area was successfully inspected by the MHRA in Q4/2018

  • Head of Process Development at Critical Pharmaceuticals
    May 2007 - Jul 2015 · 8 yrs 3 mos

    • Took an academic idea for a supercritical fluid process and transformed it into a commercially operable manufacturing process for pharmaceutical formulations • Automated the company’s supercritical fluid process using a PID control system • Managed the process development team to operate the supercritical fluid process for formulation development of company’s and clients products • Industrial supervisor to 3 PhD students

  • Supercritical Fluid Scientist at Critical Pharaceuticals
    Mar 2006 - May 2007 · 1 yr 3 mos

    Operated and maintained the CriticalMix supercritical fluid process